DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $262,051 | +162.1% | 8,391 | +345.1% | 0.00% | – |
| Q1 2021 | $100,000 | -86.7% | 1,885 | -80.8% | 0.00% | – |
| Q4 2020 | $754,000 | +579.3% | 9,836 | +229.4% | 0.00% | – |
| Q3 2020 | $111,000 | -17.8% | 2,986 | -40.6% | 0.00% | – |
| Q2 2020 | $135,000 | +1587.5% | 5,031 | +956.9% | 0.00% | – |
| Q1 2020 | $8,000 | -92.4% | 476 | -92.1% | 0.00% | – |
| Q4 2019 | $105,000 | +43.8% | 6,023 | +25.4% | 0.00% | – |
| Q3 2019 | $73,000 | -12.0% | 4,802 | +20.4% | 0.00% | – |
| Q2 2019 | $83,000 | +538.5% | 3,990 | +515.7% | 0.00% | – |
| Q4 2018 | $13,000 | +85.7% | 648 | +105.7% | 0.00% | – |
| Q3 2018 | $7,000 | +250.0% | 315 | +162.5% | 0.00% | – |
| Q2 2018 | $2,000 | – | 120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |